Sumeet Jindal
Ophthalmology · Oxford, NCNPI 1023540010
Payments from drug & device makers
Across 61 payments — averaging $76.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$862
- Merz North America, Inc.$127
- Rayner Intraocular Lenses Limited$88
- AbbVie$46
- plus $169 from 9 others
What the payments were for
- Consulting fees$1,50032%
- Travel & lodging$1,27827%
- Food & beverage$1,90241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 8 | $1,820 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $1,569 |
| Alcon | 22 | $862 |
| Merz North America, Inc. | 1 | $127 |
| Rayner Intraocular Lenses Limited | 4 | $88 |
| AbbVie | 2 | $46 |
| Revance Therapeutics, Inc. | 1 | $35 |
| Glaukos Corporation | 1 | $19 |
| Conmed Corporation | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| LKC Technologies, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$1,500
- RXSIGHT INJECTOR CARTRIDGE$1,500
- LIGHT ADJUSTABLE LENS (LAL)$1,500
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,500
- RXSIGHT INJECTOR HANDPIECE$1,500
- OPHTHALMIC INSTRUMENTS$1,059
- TRULIGN TORIC$1,059
- ENVISTA$1,059
- CRYSTALENS$1,059
- Hydrus Microstent$225
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$137
- XEOMIN$127
- LenSx$116
How this compares
$4,681 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 99 | $2,900 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 214 | $2,478 |
| Ketorolac Tromethamine | 86 | $1,798 |
| MoxifloxacinMoxifloxacin Hcl | 49 | $964 |
| Brimonidine Tartrate | 19 | $528 |
| Latanoprost | 51 | $423 |
| Timolol Maleate | 31 | $417 |
| Cephalexin | 14 | $177 |
| Methylprednisolone | 13 | $124 |
| Celecoxib | 18 | $83 |
| Gabapentin | 18 | $36 |
| Lorazepam | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Oxford
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Rajiv ShahWinston Salem$1.3M
- Patrick KeltyHickory$1.1M
- Julie WoodwardDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.